A discussion regarding how structural defects in the nucleotide-binding domain 1 (NBD1) and interactions with proteostasis pathways contribute to the differential responsiveness of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants to small-molecule correctors.